ArticleScientific reports2025
Green synthesis and functional evaluation of zinc oxide nanoparticles from red dragon fruit peel.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using red dragon fruit peel extract (RDPE) as a biogenic reducing and stabilizing agent, this paper presents an inexpensive, eco-friendly and simple biogenic synthesis of zinc oxide nanoparticles (ZnONPs). These biogenic materials are non-hazardous, environmentally friendly, and incur minimal costs compared to chemical approaches. The successful biosynthesis of ZnONPs was confirmed using several characterization tests, including UV-Vis spectroscopy, particle size analysis, zeta potential analysis, Fourier transform infrared spectroscopy, thermogravimetric analysis, X-ray diffraction spectroscopy, Field-emission scanning electron microscopy and Energy dispersive X-ray spectroscopy. In addition, a Taguchi experimental design was employed to optimize the synthesis conditions, resulting in nine formulations that incorporated the effects of two zinc salt precursors (acetate and nitrate). Among these, acetate-derived ZnONPs produced the desired hydrodynamic size (203.97 ± 1.53 nm) and best colloidal stability (zeta potential: - 29.4 ± 0.89 mV) with formulation AR7. The hexagonal wurtzite phase with a crystallite size of 18.00 ± 5.32 nm was verified by X-ray diffraction. FTIR spectra showed the presence of phytochemical functional groups in charge of capping and reduction. FESEM revealed unique flower-like morphology, with an average particle size of 45.85 ± 4.64 nm, proving the efficacy of AR7 as the optimal formulation. The antimicrobial activity tests revealed minimum inhibitory concentration values of 2.50-5.00 µg/mL against Escherichia coli, Staphylococcus aureus, and Candida albicans; while an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.